Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|October 1, 2010
Intertek Pharmaceutical Services at ICSE 2010
The Intertek Team will be launching some important new and expanded services at ICSE 2010. New services include GMP Microbiology Services and expanded capabilities for Extractable / Leachable studies.
Advertisement
ICSE Booth: 4BIO34
The Intertek Team will be launching some important new and expanded services at ICSE 2010. New services include GMP Microbiology Services and expanded capabilities for Extractable / Leachable studies.
Breaking news at the Intertek centre of excellence for biopharmaceutical characterization in Manchester brings a significant increase in LC-MS/MS characterization capabilities for protein and antibody therapeutics contributing to our existing protein characterization suite catering for all requirements of the ICHQ6B Guidelines. Capabilities include peptide mapping, amino acid analysis, amino acid sequencing, PTM and glycosylation analysis and more. Intertek are happy to announce a FREE SEMINAR on the 23rd of Nov in Manchester focusing on the requirements of ICH Q6B and the analytics to achieve compliance. Please contact us to request further information or drop by the ICSE stand to find out more.
Come meet the team to find out about our latest facility expansion which has seen our GMP facility in Athlone Ireland significantly increase its laboratory footprint and find out about our new GLP facility in Basel, Switzerland. Our team is ready to answer any questions you may have about or GLP bioanalytical, GMP pharmaceutical analysis and GMP microbiology capabilities. We look forward to meeting you in Paris!
Advertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5